Why the study?
Does intracoronary human monomeric adiponectin improve coronary blood flow and cardiac function in anesthetized pigs?
Does intracoronary human monomeric adiponectin improve coronary blood flow and cardiac function in anesthetized pigs?
Human monomeric adiponectin acutely increases coronary blood flow and cardiac contractility/relaxation through adiponectin 1 receptors, β2-adrenoceptors, and NO release in a porcine model.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open translation of porcine adiponectin effects to human coronary disease.
Adiponectin, the most abundant adipokine released by adipose tissue, appears to play an important role in the regulation of vascular endothelial and cardiac function. To date, however, the physiological effects of human monomeric adiponectin on the coronary vasculature and myocardial systo-diastolic function, as well as on parasympathetic/sympathetic involvement and nitric oxide (NO) release, have not yet been investigated. Thus, we planned to determine the primary in vivo effects of human monomeric adiponectin on coronary blood flow and cardiac contractility/relaxation and the related role of autonomic nervous system, adiponectin receptors, and NO. In 30 anesthetized pigs, human monomeric adiponectin was infused into the left anterior descending coronary artery at constant heart rate and arterial blood pressure, and the effects on coronary blood flow, left ventricular systo-diastolic function, myocardial oxygen metabolism, and NO release were examined. The mechanisms of the observed hemodynamic responses were also analyzed by repeating the highest dose of human monomeric adiponectin infusion after autonomic nervous system and NO blockade, and after specific adiponectin 1 receptor antagonist administration. Intracoronary human monomeric adiponectin caused dose-related increases of coronary blood flow and cardiac function. Those effects were accompanied by increased coronary NO release and coronary adiponectin levels. Moreover, the vascular effects of the peptide were prevented by blockade of β2-adrenoceptors and NO synthase, whereas all effects of human monomeric adiponectin were prevented by adiponectin 1 receptor inhibitor. In conclusion, human monomeric adiponectin primarily increased coronary blood flow and cardiac systo-diastolic function through the involvement of specific receptors, β2-adrenoceptors, and NO release.
No takes yet. Share an insight, caveat, or question.
Grossini et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: